Targeting protein serine/threonine phosphatases for drug development.
With the recent clinical success of drugs targeting protein kinase activity, drug discovery efforts are focusing on the role of reversible protein phosphorylation in disease states. The activity of protein phosphatases, enzymes that oppose protein kinases, can also be manipulated to alter cellular signaling for therapeutic benefits. In this review, we present protein serine/threonine phosphatases as viable therapeutic targets, discussing past successes, current challenges, and future strategies for modulating phosphatase activity.
McConnell
Jamie L
JL
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-6600, USA.
Wadzinski
Brian E
BE
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D020134:Catalytic Domain; D055808:Drug Discovery; D004789:Enzyme Activation; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D046912:Multiprotein Complexes / Q000037:antagonists & inhibitors; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors / Q000502:physiology*; D010766:Phosphorylation; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors / Q000502:physiology*
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D046912:Multiprotein Complexes; D010749:Phosphoprotein Phosphatases; D017027:Protein Tyrosine Phosphatases